GlassScriptPhysician profile
Elliot Thomas Min
NPI 1134510589
$53,202.71
in general payments reported to CMS, 2019-2025
29 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $356 · 2021: $1,688 · 2022: $48K · 2023: $715 · 2024: $867 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $47,516.40 | 2022 | |
| Synthes Gmbh | $1,055.13 | 2019 | |
| Medtronic, INC. | $956.88 | 2021-2023 | Mazor X System |
| Stryker Corporation | $774.76 | 2021 | |
| Augmedics INC. | $294.41 | 2020-2021 | |
| Spineology INC. | $286.22 | 2021 | |
| Nuvasive, INC. | $272.04 | 2020-2022 | |
| Boston Scientific Corporation | $254.19 | 2023 | Wavewriter Alpha Prime 16 |
| Globus Medical, INC. | $229.61 | 2022-2023 | Excelsius3d Imaging System |
| Ucb, INC. | $206.17 | 2024-2025 | Rystiggo, Zilbrysq, Briviact |
| Lilly USA, LLC | $187.22 | 2024-2025 | Kisunla, Amyvid |
| Medtronic USA, INC. | $180.42 | 2019-2020 | |
| Neurelis, INC. | $112.59 | 2023-2025 | Valtoco |
| Eisai INC. | $85.81 | 2024-2025 | |
| Argenx US, INC. | $84.67 | 2024-2025 | Vyvgart Hytrulo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $83.10 | 2023-2025 | |
| Kls-Martin L.P. | $81.51 | 2024 | |
| Alnylam Pharmaceuticals INC. | $74.79 | 2024-2025 | Onpattro, Amvuttra |
| Alphatec Spine, INC | $69.49 | 2024 | Solus Alif |
| Lundbeck LLC | $67.60 | 2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $64.86 | 2024-2025 | Austedo Xr, Ajovy |
| Abbvie INC. | $60.69 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $54.94 | 2024 | Nuplazid |
| Csl Behring | $31.94 | 2025 | Hizentra |
| Ipsen Biopharmaceuticals, INC | $27.79 | 2024 | Dysport |
| Bioventus LLC | $26.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.49 | 2024 | |
| Integra Lifesciences Corporation | $20.47 | 2023 | Codman Hakim, Cusa Clarity, Codman Certas |
| Zimmer Biomet Holdings, INC. | $18.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Min listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.